SUSAN ALBERT: Open Payments
NPI 1982287017 · WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,218 in 83 payments from 19 companies in 2025. Trend: 2023 $593 · 2024 $1,292 · 2025 $1,218
Food & beverage: $1,218
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $301 |
| ABBVIE INC. | 19 | $255 |
| GlaxoSmithKline, LLC. | 11 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $76 |
| Electromed, Inc. | 5 | $72 |
| PFIZER INC. | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $47 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
Products named: VRAYLAR, TRELEGY ELLIPTA, Wegovy, CAPLYTA, SMARTVEST, Ozempic, FANAPT, XIFAXAN.
Industry payments across PA — which companies pay providers there.
